Menopausal hormone therapy and hypertension: minimizing risk

Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement

People living with resistant hypertension (RH) are at high risk of adverse cardiovascular events. The British and Irish Hypertension Society has identified suspected RH as a condition for which specialist guidance may improve rates of blood pressure control and help clinicians identify those individuals who may benefit from specialist review. In this position statement we provide a practical approach for the investigation and management of adults with RH. We highlight gaps in the current evidence and identify important future research questions. Our aim is to support the delivery of high-quality and consistent care to people living with RH across the UK and Ireland.

Determinants and prediction of hypertension among Chinese middle-aged and elderly adults with diabetes: A machine learning approach

Objective

Multimorbidity, particularly diabetes combined with hypertension (DCH), is a significant public health concern. Currently, there is a gap in research utilizing machine learning (ML) algorithms to predict hypertension risk in Chinese middle-aged and elderly diabetic patients, and gender differences in DCH comorbidity patterns remain unclear. We aimed to use ML algorithms to predict DCH and identify its determinants among middle-aged and elderly diabetic patients in China.

Study design

Cross-sectional study.

Methods

Data were collected on 2775 adults with diabetes aged ≥45 years from the 2015 China Health and Retirement Longitudinal Study. We employed nine ML algorithms to develop prediction models for DCH. The performance of these models was evaluated using the area under the curve (AUC). Additionally, we conducted variable importance analysis to identify key determinants.

Results

Our results showed that the best prediction models for the overall population, men, and women were extreme gradient boosting (AUC = 0.728), light gradient boosting machine (AUC = 0.734), and random forest (AUC = 0.737), respectively. Age, waist circumference, body mass index, creatinine level, triglycerides, taking Western medicine, high-density lipoprotein cholesterol, blood urea nitrogen, total cholesterol, low-density lipoprotein cholesterol, and sleep disorders were identified as common important predictors by all three populations.

Conclusions

ML algorithms showed accurate predictive capabilities for DCH. Overall, non-linear ML models outperformed traditional logistic regression for predicting DCH. DCH predictions exhibited variations in predictors and model accuracy by gender. These findings could help identify DCH early and inform the development of personalized intervention strategies.

Hormone Replacement Therapy and Psoriasis Risk: A Nationwide Population-Based Cohort Study

BACKGROUND

Hormone replacement therapy (HRT) is used to relieve menopause symptoms, but has been reported to be associated with coronary heart disease and cancers in women. However, a link between HRT and psoriasis has yet to be established. The aim of this study was to determine the association between HRT and the risk of psoriasis.

METHODS

We executed a nationwide population-based study. A total of 1,130,741 post-menopause women were enrolled in the national health care insurance database based on the enrollment criteria. The study population was classified into four groups based on the duration of the HRT, and the risk of psoriasis was analyzed.

RESULTS

The incidence rates of psoriasis per 1,000 person-years were 3.36 and 4.09 in the no history of HRT and ≥ 5 years of HRT, respectively. After adjustment for age, smoking, alcohol intake, regular exercise, body mass index, diabetes mellitus, hypertension, and dyslipidemia, the most prolonged duration of the HRT group (≥ 5 years) exhibited significantly increased risk of developing psoriasis (hazard ratio, 1.22; 95% confidence interval, 1.16-1.29).

CONCLUSION

We propose that HRT in post-menopausal women is associated with an increased likelihood of psoriasis development.

Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?

Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.

Effects of endocrine disorders on lipids and lipoproteins

Endocrine diseases may be associated with dyslipidaemia and may increase atherosclerotic cardiovascular disease (ASCVD) risk. This chapter describes changes in lipids and lipoproteins in diseases of the pituitary, thyroid, adrenal glands, ovaries, and testes, the mechanisms for these changes, ASCVD risk in these endocrine disorders, and whether treatment of the endocrine disorder improves the lipid profile and reduces ASCVD risk. Acromegaly, GH deficiency, Cushing syndrome, chronic glucocorticoid replacement, hypothyroidism, PCOS and male hypogonadism can increase LDL-C and/or TG. Marked reductions in LDL-C are associated with hyperthyroidism, and extremely low HDL-C levels with testosterone and/or other anabolic steroid abuse. Acromegaly, GH deficiency, Cushing syndrome, and chronic glucocorticoid replacement are associated with increased ASCVD risk. Treatment of acromegaly, GH deficiency, hypothyroidism, Cushing syndrome, and testosterone deficiency reduce LDL-C, although statin therapy may still be needed. Effects on ASCVD are not known.